Cover Image
市場調查報告書

Nordmark Arzneimittel GmbH & Co. KG的產品平台分析

Nordmark Arzneimittel GmbH & Co. KG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 295950
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Nordmark Arzneimittel GmbH & Co. KG的產品平台分析 Nordmark Arzneimittel GmbH & Co. KG - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 24 Pages
簡介

Nordmark Arzneimittel GmbH & Co. KG是總公司設置於德國的製藥企業,胰酶粉、肝素鈉(Ph.Eur)等API及醫藥品的開發與商品化。其他也從事細胞株的開發、培養、蛋白質萃取純化、增殖、處方開發、臨床樣品製造、臨床實驗支援、考察法規等。

本報告提供Nordmark Arzneimittel GmbH & Co. KG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Nordmark Arzneimittel GmbH & Co. KG 基本資料

  • Nordmark Arzneimittel GmbH & Co. KG 概要
  • 主要資訊
  • 企業資料

Nordmark Arzneimittel GmbH & Co. KG :R&D概要

  • 主要的治療範圍

Nordmark Arzneimittel GmbH & Co. KG :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Nordmark Arzneimittel GmbH & Co. KG :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Nordmark Arzneimittel GmbH & Co. KG:藥物簡介

  • ancrod
  • burlulipase
  • Enzyme for Undisclosed Indication

Nordmark Arzneimittel GmbH & Co. KG :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Nordmark Arzneimittel GmbH & Co. KG :開發暫停中的計劃

Nordmark Arzneimittel GmbH & Co. KG :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06928CDB

Summary

Global Markets Direct's, 'Nordmark Arzneimittel GmbH & Co. KG - Product Pipeline Review - 2015', provides an overview of the Nordmark Arzneimittel GmbH & Co. KG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nordmark Arzneimittel GmbH & Co. KG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Nordmark Arzneimittel GmbH & Co. KG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Nordmark Arzneimittel GmbH & Co. KG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Nordmark Arzneimittel GmbH & Co. KG's pipeline products

Reasons to buy

  • Evaluate Nordmark Arzneimittel GmbH & Co. KG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Nordmark Arzneimittel GmbH & Co. KG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Nordmark Arzneimittel GmbH & Co. KG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Nordmark Arzneimittel GmbH & Co. KG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nordmark Arzneimittel GmbH & Co. KG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Nordmark Arzneimittel GmbH & Co. KG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Nordmark Arzneimittel GmbH & Co. KG Snapshot
    • Nordmark Arzneimittel GmbH & Co. KG Overview
    • Key Information
    • Key Facts
  • Nordmark Arzneimittel GmbH & Co. KG - Research and Development Overview
    • Key Therapeutic Areas
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Products Glance
    • Nordmark Arzneimittel GmbH & Co. KG - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Nordmark Arzneimittel GmbH & Co. KG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Nordmark Arzneimittel GmbH & Co. KG - Drug Profiles
    • ancrod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • burlulipase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Enzyme for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Analysis
    • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Products by Target
    • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Products by Route of Administration
    • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Products by Molecule Type
    • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Products by Mechanism of Action
  • Nordmark Arzneimittel GmbH & Co. KG - Dormant Projects
  • Nordmark Arzneimittel GmbH & Co. KG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ancrod
  • Nordmark Arzneimittel GmbH & Co. KG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Nordmark Arzneimittel GmbH & Co. KG, Key Information
  • Nordmark Arzneimittel GmbH & Co. KG, Key Facts
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Indication, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Stage of Development, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Monotherapy Products in Pipeline, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Phase I, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Preclinical, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Discovery, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Target, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Route of Administration, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Molecule Type, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Products by Mechanism of Action, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Dormant Developmental Projects,2015
  • Nordmark Arzneimittel GmbH & Co. KG - Discontinued Pipeline Products, 2015
  • Nordmark Arzneimittel GmbH & Co. KG, Subsidiaries

List of Figures

  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Top 10 Indication, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Stage of Development, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Monotherapy Products in Pipeline, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Top 10 Target, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Top 10 Route of Administration, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline by Top 10 Molecule Type, 2015
  • Nordmark Arzneimittel GmbH & Co. KG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top